Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant Non-Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab

被引：37

作者：

Kelly, Ronan J. ^{[1
]}

Carter, Corey ^{[2
]}

Giaccone, Giuseppe ^{[1
]}

机构：

[1] NCI, Mark O Hatfield Clin Res Ctr, Bethesda, MD 20892 USA

[2] USN, Natl Med Ctr, Bethesda, MD 20084 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 28期

关键词：

PHASE-II TRIAL; DIMERIZATION INHIBITOR; OVEREXPRESSION; EXPRESSION; GEFITINIB; CARCINOMA; GEMCITABINE; PERTUZUMAB; MUTATIONS; CISPLATIN;

D O I：

10.1200/JCO.2010.29.3126

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：E507 / E510

页数：4

共 26 条

[1]

Ardizzoni A, 2001, CANCER-AM CANCER SOC, V92, P1896, DOI 10.1002/1097-0142(20011001)92:7<1896::AID-CNCR1707>3.3.CO

[2]

2-S

[3]

Brabender J, 2001, CLIN CANCER RES, V7, P1850

[4] HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer [J].

Cappuzzo, F ;

Bemis, L ;

Varella-Garcia, M .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (24) :2619-2621

[5] Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients [J].

Cappuzzo, F ;

Varella-Garcia, M ;

Shigematsu, H ;

Domenichini, I ;

Bartolini, S ;

Ceresoli, GL ;

Rossi, E ;

Ludovini, V ;

Gregorc, V ;

Toschi, L ;

Franklin, WA ;

Crino, L ;

Gazdar, AF ;

Bunn, RA ;

Hirsch, FR .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5007-5018

[6] Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2 -: 39810:: A Phase II trial of cancer and leukemia group B [J].

Clamon, G ;

Herndon, J ;

Kern, J ;

Govindan, R ;

Garst, J ;

Watson, D ;

Green, M .

CANCER, 2005, 103 (08) :1670-1675

[7] PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Gale, Christopher-Michael ;

Lifshits, Eugene ;

Gonzales, Andrea J. ;

Shimamura, Takeshi ;

Zhao, Feng ;

Vincent, Patrick W. ;

Naumov, George N. ;

Bradner, James E. ;

Althaus, Irene W. ;

Gandhi, Leena ;

Shapiro, Geoffrey I. ;

Nelson, James M. ;

Heymach, John V. ;

Meyerson, Matthew ;

Wong, Kwok-Kin ;

Janne, Pasi A. .

CANCER RESEARCH, 2007, 67 (24) :11924-11932

[8] Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer [J].

Gatzemeier, U ;

Groth, G ;

Butts, C ;

Van Zandwijk, N ;

Shepherd, F ;

Ardizzoni, A ;

Barton, C ;

Ghahramani, P ;

Hirsh, V .

ANNALS OF ONCOLOGY, 2004, 15 (01) :19-27

[9] ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling [J].

GrausPorta, D ;

Beerli, RR ;

Daly, JM ;

Hynes, NE .

EMBO JOURNAL, 1997, 16 (07) :1647-1655

[10]

Heinmöller P, 2003, CLIN CANCER RES, V9, P5238

← 1 2 3 →